Expected value of the additional state in evaluating the method of quantification and uncertainty of additional states in an analytical model of grade I hypertension by Takeshi Uchikura et al.
Uchikura et al. Journal of Pharmaceutical Health Care and Sciences  (2015) 1:3 
DOI 10.1186/s40780-014-0006-zRESEARCH ARTICLE Open AccessExpected value of the additional state in
evaluating the method of quantification and
uncertainty of additional states in an analytical
model of grade I hypertension
Takeshi Uchikura1,2*, Makoto Kobayashi3, Masayuki Hashiguchi1 and Mayumi Mochizuki1Abstract
Background: In the construction of pharmacoeoconomic models, simplicity is desirable for transparency (people
can see how the model is built), ease of analysis, validation (how well the model reproduces reality), and
description. Few reports have described concrete methods for constructing simpler models. Therefore we focused
on the value of additional states and uncertainty in disease models with multiple complications.
Objectives: The objective of this study was to examine the possibility of ranking additional states in disease models
with multiple complications using a method for evaluating the quantification and uncertainty of additional states.
Methods: The expected value of additional states (EVAS) was formulated to calculate the value of additional states
from the variation between analytic models using the net benefit method, and uncertainty was subtracted from the
variation. We also verified the usefulness and availability of this method in grade I hypertension as a verification of the
disease model. We assumed that stroke was recognized as an associated complication of hypertension in the basic
model. In addition, stroke recurrence, coronary heart disease (CHD), and end-stage renal disease (ESRD) were assumed
to represent other complications of hypertension. Ten thousand Monte Carlo simulations were performed, and the
probability distribution was assumed to be the beta distribution in clinical parameters. The ranges of clinical parameters
were ±6.25%, 12.5%, 25%, and 50% of the standard deviation from the mean value.
Results: The EVAS in complications of CHD showed the greatest uncertainty. In contrast, the EVAS of ESRD differed
from stroke recurrence in the value ranking by uncertainty.
Conclusions: The EVAS has the potential to determine the ranking of additional states based on the quantitative value
and uncertainty in disease models with multiple complications.
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Pharmacoeoconomic model analysis is conducted to
combine various parameters (effect, side effects, quality
of life [QOL], and cost data) using modeling techniques,
e.g., the Markov model [1]. The construction of analytic
models is a key issue affecting their results. The guidelines* Correspondence: take-u@cmed.showa-u.ac.jp
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unless otherwise stated.for modeling analysis refer to internal validity, e.g., the
course of a disease or clinical process, and external vali-
dity, e.g., comparing model results with real-world results
[2,3]. Thus, The Joint Report of the International Society
for Pharmacoeconomics and Outcomes Research and
the Society for Medical Decision Making (report of the
ISPOR-SMDM Modeling Good Research Practices Task
Force-2 [4]) mentions that the simplicity of models is
desirable for ease of analysis, description, transparency
(people can see how the model is built), and validation
(how well the model reproduces reality) [5]. However, fewal. This is an Open Access article distributed under the terms of the Creative
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simpler models.
Generally, in the construction of analytical (disease)
models, we assume that multiple complications may
occur as the outcome of a specific disease. The compli-
cations in the analytical model are selected based on
their importance (generally referred to as “a state”), but
currently there is no evaluation method for that purpose.
Furthermore, it is important to consider the influence of
the uncertainty of the state itself, but that is not done at
present. Therefore, if we could attempt to estimate the
quantitative value of additional states in an analytical
model and examine the possibility of ranking additional
states in disease models with multiple complications, it
would contribute to the establishment of useful analy-
tical models. Therefore, in this study we attempted to
estimate the quantitative value of additional states and
rank those additional states, in addition to evaluating the
robustness of ranking while considering uncertainty.
Objectives
The objective of this study was to examine the possi-
bility of ranking additional states in disease models with
multiple complications using a method for evaluating
the quantification and uncertainty of additional states.
Methods
Method to evaluate quantification of the value of
additional states and uncertainty of transition
probabilities
We applied the net benefit method [6] to estimate the
quantification of the value of additional states. This
method assumes a net monetary benefit and a net health
benefit in the same index using the threshold (e.g., 1
quality-adjusted life year [QALY] = 5 million yen) of an
incremental cost-effectiveness ratio, and evaluates inter-
vention effects in the single index as the result of cost-
effectiveness analysis. This evaluation converts costs and
QALY into the same index using a threshold (λ) by ap-
plying the concept of net benefit and subsequently adds
these values as components of the value of the states.
Specifically, analytical model A is is the basic model, and
analytical model B reflects the addition of a specific
complication as an additional state to analytical model
A. We estimated the value of the additional state as the
change in the cost and effectiveness for the net benefit
between the two models using Eq. (1):
Value of additional state ¼ CB–CAð Þ=λ þ EA–EBð Þ・・・・
ð1Þ
where CA = the cost of analytical model A, CB = the
cost of analytical model B, λ = 5,000,000 yen (the value
of 1 QALY), EA = the effectiveness (QALY) of analyticalmodel A, and EB = the effectiveness (QALY) of analytical
model B.
Then, we defined the expected value of the additional
state (EVAS) as the true value of the additional state,
taking into account the robustness of the results with
the uncertainty of the occurrence of the additional state,
and estimated the value using Eq. (2). The uncertainty of
the additional state based on the transition probabilities
is calculated as the absolute value of the difference in
the value of the additional state and a trial value in
Monte Carlo simulations. Monte Carlo simulations are
recognized as a useful method for performing multiple
simulations of a model to obtain stable estimates of its
variability [1,7]. In addition, the cumulative values were
obtained from 10,000 Monte Carlo simulations of “the
value of the additional state” and “the uncertainty of
additional state.”
EVAS ¼ value of the additional state
– uncertainty of that additional state・・・・
ð2Þ
Using Eq. (1), we can calculate each value of multiple
complications (states) assumed in a specific disease
based on costs and QALY and rank these complications
(states) in the analytical model. Furthermore, we can es-
timate the robustness of the results based on the uncer-
tainty of each state itself by estimating the EVAS from
Eq. (2). Therefore, we can select a specific complication
among multiple complications of a disease, because this
method ranks multiple complications that consider the
values of additional states and the robustness of the
value of uncertainty of additional states.
Disease model used for examining the ranking of the
values of additional states
We examined this evaluation method in hypertension, be-
cause it is a chronic model known to be associated with
multiple complications. The basic model referred to the
Markov model of grade I hypertension reported previously
[8]. We did not assume an intervention effect for hyper-
tension, because this model is less for pharmacoeconomic
evaluation than for determining the value of additional
states. The basic model covers stroke that is recognized as
associated with hypertension [9]. In addition, stroke recur-
rence, coronary heart disease (CHD), and end-stage renal
disease (ESRD) were assumed to represent other compli-
cations resulting from hypertension (Figure 1).
Transition probabilities, QOL, and cost data on states in
the disease model
The hypothetical patients were assumed to be 55-year-old
men, and the analytical time line was 10 years, because
the Japan Public Health Center (JPHC) study [10] of
Figure 1 The basic (stroke) model and each analytical model that assumed an additional state (complication). HTN: hypertension, CHD:
coronary heart disease, ESRD: end-stage renal disease.
Table 1 Clinical parameters
Mean
Annual incidence of stroke in grade I hypertension
(1000 people/year)
Men [10] 4.9
Annual incidence of CHD in grade I hypertension
(1000 people/year)
Men [10] 1.17
Annual incidence of ESRD in grade I hypertension
(1000 people/year)
Men [11] 0.21
Recurrence rate of stroke [12]*
First year 12.9%
Second to fifth year 8.2%






Mortality after CHD [14,15]
In hospital 7%
One year (1000 people/year) 20.4
Mortality after ESRD [16]
One year 9.7%
*Sixth year and thereafter use the same parameter as the fifth year.
†Mortality after recurrence of stroke uses the same parameter.
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who had an average age of 56.0 years and the follow-up
period was 11.0 years. We also used the annual incidences
of stroke and CHD in patients with grade I hypertension
(1000 persons/year) reported in the JPHC study [10]. The
incidence of ESRD was also used as epidemiologic data in
patients with grade I hypertension [11]. The rate of stroke
recurrence and mortality after stroke, CHD, and ESRD
were calculated from Japanese epidemiologic data [12-16].
The fifth-year parameter of stroke and the first-year par-
ameter of mortality from CHD were used for the subse-
quent year and thereafter (Table 1). Nonstroke mortality
was calculated based on the death rate of the Japanese
population stratified by age [17].
The degree of disability after stroke was scored using
the modified Rankin Scale (mRS) [18,19], and allocations
of patients were derived from the proportion of stroke
type and mRS score at hospital discharge [20,21]. The
degree of disability was assumed to remain constant over
time.
Utilities for patients with disability after stroke and
ESRD were based on Japanese data [22,23] and those
after CHD were based on non-Japanese (UK) data [24]
The utilities of health (hypertension alone) and death
were assumed to be 1 and 0, respectively (Table 2).
The cost of stroke treatment in the acute phase was
obtained from the average number of hospitalized days
based on the highest number of diagnostic procedure
combinations in patients with each type of stroke [25].
The cost of recovery-phase rehabilitation facility care
was calculated based on an average of 88 hospitalized
days [26]. The annual cost of care was estimated from
Table 2 Utility in patients after stroke, CHD, and
ESRD [22-24]
mRS 0* mRS 1 mRS 2 mRS 3 mRS 4 mRS 5 Death
Stroke 1* 0.83 0.67 0.45 0.24 0.09 0*
CHD† First year: 0.68, second year or later: 0.72
ESRD 0.75
*Assumed in this analysis.
†Data obtained from acute MI patients.
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allowances for nursing care per month [27], which cor-
respond to mRS scores of 2–5, and it was calculated
until death. In addition, we calculated work lost until the
age of 65 years if the patients died at age 64 years or
younger.
The cost of CHD treatment for myocardial infarction
(MI) in the acute phase was obtained from actual
hospitalization costs (an average of 25 hospitalized days)
[28]. The costs of nursing care and work lost (excluding
hospitalization in the acute phase) were not included,
because CHD has relatively little affect on physical func-
tions. The cost of ESRD treatment was assumed to be
represented by that for dialysis [23] and conservative
management [29] (Table 3; see Additional file 1).
The data on medical costs were obtained from official
prices in Japan [25,30,31]. The costs of work loss reflected
the average wages of each age cohort for regular em-
ployees [32].Discounting
This study assumed that the discount rate was 3% and
0% (no discounts) for reference values.External validity
The external validity of analytical models compared the
overall mortality from grade I hypertension patents in
the JPHC Study [10] with the overall mortality of each





After stroke First year mRS0-1 ●
mRS2-5 ● ●
Second year or later mRS0-1
mRS2-5
After CHD First year - ●
Second year or later -
After ESRD - -Statistical analyses
Ten thousand Monte Carlo simulations were performed
for each evaluation. The probability distribution for transi-
tion probabilities was assumed to be the beta distribution
[33]. The ranges of transition probabilities were ±6.25%,
12.5%, 25%, and 50% of the standard deviation (SD) from
the mean. The simulation software TreeAge2013 (Tree-
Age Software, Inc. USA) was used.
Results
Evaluation of external validity
The overall mortality rate per year from the JPHC Study
[10] was 0.0084, in the basic model (stroke alone) it was
0.0086, in the stroke-recurrence model it was 0.0087, in
the stroke-CHD model it was 0.0087, and in the stroke-
ESRD model it was 0.0086.
Evaluation of the value of additional states
The values of additional states (complications) in the
grade I hypertension model were 116 (92 for cost) for
stroke recurrence, 295 (122 for cost) for CHD, 137 (100
for cost) for ESRD with dialysis, and 53 (16 for cost) for
ESRD with conservative management (units are QALY).
No differing trend was seen when no discount was as-
sumed (Table 4).
Evaluation of the EVAS
The EVAS when uncertainty was considered tended to be-
come smaller if the variable of the transition probabilities
of the state grew larger. However, the ranking of ad-
ditional states did not differ markedly when uncertainty
was not taken into consideration. Therefore, the EVAS of
CHD was the greatest of the additional states examined,
even when the SD was ±50%, and the EVAS of ESRD with
conservative management was the least in each case. In
contrast, the EVAS of ESRD with dialysis was greater than
that for stroke recurrence when uncertainty was not
considered and reached 84 when the SD was ±50%. This
estimate was less than the 89 for the EVAS of stroke re-
currence when the SD was ±25% (Table 4).reatment and others after stroke, CHD, and ESRD
y-phase
t





● ● (for clinic visits)
● ● ●
● ● (in hospital)
● ● (for clinic visits)
● (hemodialysis or conservative
management)
● (for clinic visit)









Recurrence of stroke 116 (140)
7 (8) 109 (132)
13 (16) 102 (124)
26 (32) 89 (108)
52 (60) 64 (80)
CHD 295 (356)
15 (18) 280 (338)
30 (36) 265 (320)
60 (72) 235 (284)
117 (142) 178 (214)
ESRD: Dialysis treatment 137 (167)
7 (8) 130 (159)
14 (16) 123 (151)
27 (33) 120 (134)
53 (64) 84 (103)
Conservative treatment 53 (65)
3 (4) 50 (61)
6 (7) 47 (58)
12 (15) 41 (50)
23 (28) 30 (37)
Cumulative values of 10,000 Monte Carlo simulations.
CHD: coronary heart disease, ESRD: end-stage renal disease.
*The value of additional state = (CB–CA)/λ+ (EA–EB).
**Uncertainty = an absolute value of the difference of the value of the
additional state (average) and the trial value of the Monte Carlo simulations.
†EVAS = the value of the additional state – the uncertainty (of the
additional state).
Figures in parentheses indicate values when the discount rate is 0%.
Uchikura et al. Journal of Pharmaceutical Health Care and Sciences  (2015) 1:3 Page 5 of 7Discussion
In an attempt to construct a simpler model, this study
ranked the importance of multiple complications in
hypertension to estimate the value of additional states in
a quantitative analytical model including transition prob-
abilities, QOL, and cost data. In addition, we evaluated
the robustness of the ranking of these values when con-
sidering the uncertainty of transition probabilities for
the EVAS. To the best of our knowledge, this was the
first experiment on quantification and ranking of the
value of states along with uncertainty.
The ranking of the value of additional states was in the
order CHD, ESRD with dialysis, stroke recurrence, and
ESRD with conservative management in the analytical
model of 55-year-old men with grade I hypertension. The
differences in the assumed treatment in ESRD influenced
the ranking of the value of the additional state, because
the cost of dialysis treatment is 100, but that of conserva-
tive treatment is 16 (the value of QALY conversion). Thus,
the ranking of ESRD with dialysis and stroke recurrencewill change with an assumption of the uncertainty of tran-
sition probabilities of the EVAS.
In the development of analytical models, the difference
in internal validity and results of analytical models must
be weighed [34,35], particularly in analytical models con-
structed by academic groups in competitions like the
Mount Hood Challenge Meeting [36]. Few reports re-
ferred to concrete methods for constructing simpler
models. If our method enables the ranking of multiple
complications in a specific model based on analytical
values, more important and robust additional states
could be identified. This would contribute to the de-
velopment of a simpler model for pharmacoeconomic
evaluation.
The limitations of this study were that: 1) only grade I
hypertension was examined; 2) the setting of the thresh-
old (λ) in this method could be refined; and 3) the va-
riation in all transition parameters was assumed to have
the same range in a state. Although only grade I hyper-
tension was considered, Eq. (2) shows that there would
be no difference in the ranking of the value of the state
based on the EVAS in other diseases. Therefore, this
method has sufficient potential to be widely applied. The
threshold (λ) was set at 5 million yen for 1 QALY
because 1 QALY in Japan was reported to be between
approximately 5 and 6 million yen [37]. However, care
must be taken because the results (the value of states)
will change based on the setting of the threshold (λ). Fi-
nally, the ranking of states (complications) may be dif-
ferent in some results from the EVAS based on
variations in transition probabilities. The variation of all
transition parameters was assumed to be in the same
range in a state in this study. However, the actual un-
certainty of transition probabilities can differ. It will be
necessary to consider this in an actual analytical model
in future.
Conclusions
This is the first report on devising a method for the
evaluation and ranking of the quantitative value of
additional states with uncertainty. It allows cumulative
evaluation of transition probabilities, QOL, and cost data
of a state using the EVAS. Generally, when we construct
a pharmacoeconomic model, we consider states based
on transition probabilities (e.g., incidence or mortality
rate), but QOL and cost data are also components of a
state. This evaluation method is useful because it quan-
tifies the value of a state. In addition, the ranking of
additional states in a disease model with multiple com-
plications can be determined to identify which have less
impact on a pharmacoeconomic model. The EVAS can
therefore take into consideration the value of additional
states with the uncertainty of transition probabilities. In
the next phase of this continuing study, we plan to
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macoeconomic evaluation, i.e., the analytic results of
interventions, and/or to examine the results in other
chronic diseases that have multiple complications, e.g.,
chronic hepatitis C, etc., because we think that it is
necessary to verify that this method will help to con-
struct a simpler analytical model.
Additional file
Additional file 1: Table S1. Disease type in stroke [20]. Table S2. mRS
scores for each type of stroke (partly modified) [21] and explanation of
each mRS [18,19]. Table S3. Breakdown of acute hospital care costs
[25,28,29]. Table S4. Breakdown of recovery-phase rehabilitation facility
care costs [26,29]. Table S5. Breakdown of ambulant treatment costs after
stroke and CHD [30,31]. Table S6. Breakdown of ambulant treatment
costs after ESRD [23,29]. Table S7. Work lost (4 h) for clinic visit [32].
Table S8. Assumed nursing-care costs [27] for each mRS score.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
Conceived and designed the experiments: UT KM HM MM. Analyzed the
data: UT. Wrote the paper: UT KM HM MM. All authors read and approved
the final manuscript.
Acknowledgments
Yuma Higashino contributed to data collection.
Author details
1Division for Evaluation and Analysis of Drug Information, Faculty of
Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512,
Japan. 2Department of Hospital Pharmaceutics, Showa University School of
Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan. 3CRECON
Medical Assessment Inc, 2-12-15 Shibuya, Shibuya-ku, Tokyo 150-0002, Japan.
Received: 25 June 2014 Accepted: 30 October 2014
References
1. Stahl JE: Modelling methods for pharmacoeconomics and health
technology assessment: An overview and guide. Pharmacoeconomics
2008, 26:131–148.
2. National Institute for Health and Clinical Excellence: The Guidelines Manual 2012.
http://www.nice.org.uk/article/PMG6/chapter/1%20Introduction.
3. Fukuda T: Guidelines for analytical methods in health economics
evaluation research. In Health and Labor Sciences Research Grant:
Research on the Health Benefit Plan Applying Health Economics Evaluation.
Tokyo; 2013.
4. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M:
Conceptualizing a model: A report of the ISPOR-SMDM Modeling Good
Research Practices Task Force-2. Med Decis Making 2012, 32:678–689.
5. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, for
the ISPOR-SMDM Modeling Good Research Practices Task Force: Model
transparency and validation: a report of the ISPOR-SMDM Modeling
Good Research Practices Task Force-7. Med Decis Making 2012,
32:733–743.
6. Claxton K, Neumann PJ, Araki S, Weinstein MC: Bayesian value-of-information
analysis. An application to a policy model of Alzheimer's disease. Int J
Technol Assess Health Care 2001, 17:38–55.
7. Naversnik K, Rojnik K: Handling input correlations in pharmacoeconomic
models. Value Health 2012, 15:540–549.
8. Uchikura T, Yokoi N, Hashiguchi M, Hashiguchi M, Mochizuki M:
Pharmacoeconomic evaluation of hypothetical over-the-counter
angiotensin-converting enzyme (ACE) inhibitors for the prevention ofstroke in patients with grade I hypertension. Yakugaku Zasshi 2011,
131:571–580.
9. Japanese Society of Hypertension: Guidelines for the Management of
Hypertension 2009. Tokyo: Japanese Society of Hypertension; 2009
[In Japanese].
10. Ikeda A, Iso H, Yamagishi K, Inoue M, Tsugane S: Blood pressure and the
risk of stroke, cardiovascular disease, and all-cause mortality among
Japanese: The JPHC study. Am J Hypertens 2009, 22:273–280.
11. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman
NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl
J Med 1996, 334:13–18.
12. Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H,
Oishi Y, Ibayashi S, Iida M: Ten year recurrence after first ever stroke in a
Japanese community: The Hisayama study. J Neurol Neurosurg Psychiatry
2005, 76:368–372.
13. Investigative Commission on Measures of Stroke: Interim Report. Tokyo:
Japanese Ministry of Health and Welfare, Health Service Bureau,
Lifestyle-Related Disease Measure Office; 1999 [In Japanese].
14. Watanabe J, Iwabuchi K, Koseki Y, Fukuchi M, Shinozaki T, Miura M,
Komaru T, Kagaya Y, Shirato K, Kitaoka S, Ishide N, Takishima T: Declining
trend in the in-hospital case-fatality rate from acute myocardial
infarction in Miyagi prefecture from 1980 to 1999. Jpn Circ J 2001,
65:941–946.
15. Japanese Coronary Artery Disease (JCAD) Study Investigators: Current
status of the background of patients with coronary artery disease in
Japan. Circ J 2006, 70:1256–1262.
16. Japanese Society for Dialysis Therapy, Committee of Renal Data Registry:
An overview of regular dialysis treatment in Japan. http://docs.jsdt.or.jp/
overview/.
17. Japanese Ministry of Health, Labor and Welfare, Minister’s Secretariat
Statistics and Information Department: 2007 Abridged Life Table. Tokyo:
Ministry of Health, Labor and Welfare; 2008. http://www.mhlw.go.jp/toukei/
saikin/hw/life/life07/index.html]. [In Japanese].
18. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J:
Interobserver agreement for the assessment of handicap in stroke
patients. Stroke 1988, 19:604–607.
19. Shinohara Y, Minematsu K, Amano T, Ohashi Y: Reliablity of modified
Rankin scale—introduction of a guidance scheme and a questionnaire
written in Japanese. Jpn J Stroke 2007, 29:6–13 [In Japanese].
20. Kobayashi S (Ed): Japanese Stroke Data Bank 2009. Tokyo: Nakayama Shoten;
2009 [In Japanese].
21. Kobayashi S (Ed): Japanese Stroke Data Bank 2005. Tokyo: Nakayama Shoten;
2005 [In Japanese].
22. Noto S, Yanagi H, Tomura S: Measuring utilities for various functional
outcomes after stroke, comparison of rating scale and time trade-off
methods. Nippon Koshu Eisei Zasshi 2002, 49:1205–1216 [In Japanese].
23. Takura T, Kawanishi H, Minakuchi J, Nagake Y, Takahashi S: Cost-effectiveness
analysis of on-line hemodiafiltration in Japan. Blood Purif 2013,
35:85–89.
24. Lacey EA, Walters SJ: Continuing inequality: gender and social class
influences on self perceived health after a heart attack. J Epidemiol
Community Health 2003, 57:622–627.
25. 2012 DPC electronic score list. [online]. [http://www.mhlw.go.jp/topics/2012/
03/tp0305-02.html]. [In Japanese].
26. Koga M, Uehara T, Nagatsuka K, Yasui N, Hasegawa Y, Naritomi H, Okada Y,
Minematsu K: Current role of convalescent rehabilitation units in
community-based referral systems for stroke patients in Japan. Jpn J
Stroke 2008, 30:735–743 [In Japanese].
27. Ministry of Health, Labor and Welfare: Public notice of no. 33 of 2000
(No. 258 revision). [In Japanese].
28. Fujimura Y: Evaluation of the diagnosis procedure combination payment
system: from the viewpoint of patients, medical and co-medical workers,
and managements. Jpn J Political Economy Health Health Care 2010, 29:29–40
[In Japanese].
29. Ikeda S, Kobayashi M: Prediction of long-term prognosis for diabetes patients.
Development of risk simulation software for cost-effectiveness analysis. Bunshi
Touyoubyougaku no Shinpo; 2003:191–194 [In Japanese].
30. Medical fees scoreboards (Ikashinryohosyu Tensuhyo). 2012th edition. Tokyo:
Shakai Hoken Kenkyujyo; 2012 [In Japanese].
31. National Health Insurance Price Dictionary (Hokenyaku Jiten). 2012th edition.
Tokyo: Jiho, Inc; 2012 [In Japanese].
Uchikura et al. Journal of Pharmaceutical Health Care and Sciences  (2015) 1:3 Page 7 of 732. Ministry of Health, Labor and Welfare, Minister’s Secretariat Statistics and
Information Department: Basic Survey on Wage Structure, 2009. Tokyo:
Ministry of Health, Labor and Welfare; 2008 [http://www.e-stat.go.jp/SG1/
estat/NewList.do?tid=000001011429]
33. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD:
ISPOR-SMDM Modeling Good Research Practices Task Force: Model
parameter estimation and uncertainty: a report of the ISPOR-SMDM
Modeling Good Research Practices Task Force—6. Med Decis Making
2012, 32:722–732.
34. Doan QV, Chiou CF, Dubois RW: Review of eight pharmacoeconomic
studies of the value of biologic DMARDs (adalimumab, etanercept, and
infliximab) in the management of rheumatoid arthritis. J Manag Care
Pharm 2006, 12:555–569.
35. Ramos GF, Kuiper S, Dompeling E, van Asselt AD, de Grauw WJ, Knottnerus
JA, van Schayck OC, Schermer TR, Severens JL: Structuring and validating a
cost-effectiveness model of primary asthma prevention amongst
children. BMC Med Res Methodol 2011, 11:150–163.
36. Palmer AJ, Clarke P, Gray A, Leal J, Lloyd A, Grant D, Palmer J, Foos V,
Lamotte M, Hermann W, Barhak J, Willis M, Coleman R, Zhang P, McEwan P,
Betz Brown J, Gerdtham U, Huang E, Briggs A, Carlsson KS, Valentine W, for
the Mount Hood 5 Modeling Group: Computer modeling of diabetes and
its complications: a report on the Fifth Mount Hood Challenge meeting.
Value Health 2013, 16:670–685.
37. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K: International
survey on willingness-to-pay (WTP) for one additional QALY gained:
what is the threshold of cost effectiveness? Health Econ 2010, 19:422–437.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
